Atlas Trials

Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL

Clinical trial NCT07493330 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07493330
Sponsor
Ruijin Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
PTCLRefractory
Start date
2026-03-23
Primary completion
2029-12-12
Enrollment
86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.